Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.45 |
| ▸ | AKT2 | P31751 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.41 |
| ▸ | FECH | P22830 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283148 | 0.90 | AKT1 (0.48) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2283718 | 0.88 | AKT1 (0.47) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2281218 | 0.87 | AKT1 (0.46) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2279173 | 0.86 | AKT1 (0.41) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2281623 | 0.86 | AKT1 (0.46) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2279260 | 0.86 | AKT1 (0.44) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2283359 | 0.85 | AKT1 (0.45) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2286684 | 0.84 | AKT1 (0.45) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL12376038 | 0.84 | AKT1 (0.45) | AKT1AKT2KCNH2AKT3FECH | |
| SCHEMBL2281090 | 0.84 | AKT1 (0.46) | AKT1AKT2KCNH2AKT3FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | claimed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | claimed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | claimed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| EP-1898903-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222321-A1 | Inhibitors of akt activtiy | PIK3CA, PIK3CD, INPP5D | AKT1 8/4885AKT2 4/4885KCNH2 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.